News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
211,131 Results
Type
Article (7956)
Company Profile (92)
Press Release (203083)
Section
Business (66692)
Career Advice (139)
Deals (11799)
Drug Delivery (14)
Drug Development (27871)
Employer Resources (27)
FDA (4475)
Job Trends (4969)
News (108062)
Policy (6423)
Tag
Academia (644)
Alliances (22022)
Alzheimer's disease (420)
Antibody-drug conjugate (ADC) (41)
Approvals (4449)
Artificial intelligence (84)
Bankruptcy (58)
Best Places to Work (4612)
Biotechnology (81)
Breast cancer (48)
Cancer (580)
Career advice (126)
CAR-T (62)
Cell therapy (178)
Clinical research (21150)
Collaboration (250)
Compensation (71)
COVID-19 (886)
C-suite (50)
Cystic fibrosis (44)
Data (536)
Diabetes (44)
Diagnostics (3040)
Earnings (22419)
Events (36680)
Executive appointments (134)
FDA (4660)
Funding (191)
Gene editing (44)
Gene therapy (87)
GLP-1 (193)
Government (697)
Healthcare (7081)
Infectious disease (915)
Inflammatory bowel disease (51)
IPO (5667)
Job creations (539)
Job search strategy (106)
Layoffs (97)
Legal (827)
Lung cancer (70)
Lymphoma (45)
Manufacturing (72)
Medical device (4476)
Medtech (4479)
Mergers & acquisitions (6239)
Metabolic disorders (114)
Neuroscience (527)
NextGen Class of 2024 (2112)
Non-profit (910)
Northern California (716)
Obesity (62)
Opinion (35)
Patents (39)
People (18529)
Phase I (8919)
Phase II (9901)
Phase III (5332)
Pipeline (245)
Postmarket research (305)
Preclinical (3703)
Press Release (55)
Radiopharmaceuticals (112)
Rare diseases (95)
Real estate (1195)
Regulatory (5243)
Research institute (665)
Series A (36)
Southern California (632)
Startups (1505)
United States (5745)
Vaccines (172)
Date
Today (36)
Last 7 days (318)
Last 30 days (1692)
Last 365 days (16061)
2024 (14680)
2023 (18660)
2022 (22049)
2021 (23847)
2020 (21282)
2019 (16852)
2018 (12210)
2017 (11313)
2016 (9975)
2015 (11744)
2014 (7538)
2013 (5728)
2012 (5604)
2011 (5647)
2010 (4832)
Location
Africa (139)
Asia (14222)
Australia (2259)
California (1577)
Canada (610)
China (122)
Colorado (60)
Connecticut (48)
Europe (31246)
Florida (152)
Illinois (99)
Indiana (57)
Kansas (55)
Maryland (233)
Massachusetts (1250)
Michigan (44)
Minnesota (64)
New Jersey (421)
New York (384)
North Carolina (294)
Northern California (716)
Ohio (55)
Pennsylvania (364)
South America (192)
Southern California (632)
Texas (212)
Utah (45)
Washington State (174)
211,131 Results for "bc platforms".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
BC Platforms and NTT Group Announce Official Opening Ceremony for Exclusive Collaboration and Launch of Japanese Precision Medicine Platform
BC Platforms, a global leader in real world data, healthcare data management, and analytics, announces an exclusive collaboration with NTT Life Science Corporation, a company in the medical field of the NTT Group, to accelerate data-driven medicine.
April 15, 2024
·
7 min read
Business
BC Platforms Appoints Mikaela Bruhammar as Chief Operating Officer, Markets
BC Platforms, a global leader in healthcare data management and analytics, announces the appointment of Mikaela Bruhammar, an experienced life sciences executive, as the company’s Chief Operating Officer, Markets.
September 12, 2023
·
4 min read
Press Releases
Zetagen Therapeutics Announces First Patients Enrolled in Phase 2a Clinical Study of ZetaMet™ (Zeta-BC-003) Metastatic Breast Cancer
November 12, 2024
·
4 min read
Drug Development
Screening Completed: Berlin Cures Achieves Key Milestone in BC 007 Phase II Trial for Treatment of Long COVID
Berlin Cures announced the successful completion of patient screening for its pan-European Phase II trial of BC 007, a novel therapeutic candidate for the treatment of Long COVID.
April 23, 2024
·
2 min read
Press Releases
Impressive preliminary objective response rates (ORR) of 36% in NSCLC and 80% in EGFRmut NSCLC: Interim Results of a Phase 1 Study of BC3195, a First-in-Class ADC Targeting CDH3, Presented by BioCity at ESMO 2024
September 23, 2024
·
4 min read
Drug Development
BC Centre for Excellence in HIV/AIDS study reveals Treatment as Prevention combined with targeted Pre-Exposure Prophylaxis can stop HIV/AIDS
July 18, 2024
·
4 min read
Drug Development
BioCity announces the first patient dosed with its anti-TIM-3 mAb BC3402 in Combination with IMFINZI for the Treatment of Advanced Hepatocellular Carcinoma in a Phase Ib/II Trial
BioCity Biopharma today announced dosing of the first patient in a Phase Ib/II clinical trial of its anti-TIM-3 monoclonal antibody (mAb) BC3402 in combination with IMFINZI (durvalumab) for the treatment of advanced hepatocellular carcinoma (HCC) in China.
December 20, 2023
·
3 min read
BC Platforms Announces USD 20 Million Growth Financing led by Jolt Capital
BC Platforms (BCP), a global leader in healthcare data management and analytics, today announced it has closed a CHF 20 million (approx. USD 20 million) financing round.
November 8, 2022
·
5 min read
Drug Development
BioCity announces the first patient dosed with its first-in-class CDH3-targeting ADC BC3195 in a Phase 1 Trial
BioCity Biopharma announced the dosing of the first patient in a Phase 1a/1b clinical trial of its first-in-class CDH3 antibody drug conjugate, BC3195 in China.
July 19, 2023
·
2 min read
Drug Development
BioCity Signs Collaboration Agreement with AstraZeneca on BC3402, a monoclonal antibody targeting anti-TIM-3, in Combination with IMFINZI (durvalumab) for the Treatment of Advanced Hepatocellular Carcinoma in China
BioCity Biopharma and AstraZeneca signed an agreement to collaborate on a Phase Ib/II clinical study to evaluate the safety and efficacy of BioCity’s BC3402, a monoclonal antibody targeting the T cell immunoglobulin and mucin domain-containing protein 3, also known as TIM-3, in combination with AstraZeneca’s anti-PD-L1 mAb IMFINZI for the treatment of advanced hepatocellular carcinoma.
September 27, 2023
·
2 min read
1 of 21,114
Next
